BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34158057)

  • 21. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
    Leiter LA; Bain SC; Hramiak I; Jódar E; Madsbad S; Gondolf T; Hansen T; Holst I; Lingvay I
    Cardiovasc Diabetol; 2019 Jun; 18(1):73. PubMed ID: 31167654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.
    Tsujikawa LM; Fu L; Das S; Halliday C; Rakai BD; Stotz SC; Sarsons CD; Gilham D; Daze E; Wasiak S; Studer D; Rinker KD; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
    Clin Epigenetics; 2019 Jul; 11(1):102. PubMed ID: 31300040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
    Sharma A; Cannon CP; White WB; Liu Y; Bakris GL; Cushman WC; Zannad F
    J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29769203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
    Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
    Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.
    Hwang YC; Morrow DA; Cannon CP; Liu Y; Bergenstal R; Heller S; Mehta C; Cushman W; Bakris GL; Zannad F; White WB
    Diabetes Obes Metab; 2018 Mar; 20(3):654-659. PubMed ID: 29064626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial.
    Schwartz GG; Ballantyne CM; Barter PJ; Kallend D; Leiter LA; Leitersdorf E; McMurray JJV; Nicholls SJ; Olsson AG; Shah PK; Tardif JC; Kittelson J
    JAMA Cardiol; 2018 Feb; 3(2):164-168. PubMed ID: 29071331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.
    Badjatiya A; Merrill P; Buse JB; Goodman SG; Katona B; Iqbal N; Pagidipati NJ; Sattar N; Holman RR; Hernandez AF; Mentz RJ; Patel MR; Jones WS
    Circ Cardiovasc Interv; 2019 Dec; 12(12):e008018. PubMed ID: 31752517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
    Cavender MA; White WB; Jarolim P; Bakris GL; Cushman WC; Kupfer S; Gao Q; Mehta CR; Zannad F; Cannon CP; Morrow DA
    Circulation; 2017 May; 135(20):1911-1921. PubMed ID: 28246236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial.
    Salahuddin T; Kittelson J; Tardif JC; Shah PK; Olsson AG; Nicholls SJ; Leitersdorf E; Leiter LA; Kallend D; Black DM; Barter PJ; Ballantyne CM; Schwartz GG
    Am Heart J; 2020 Mar; 221():60-66. PubMed ID: 31927126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation.
    Zhong Z; Hou J; Zhang Q; Zhong W; Li B; Li C; Liu Z; Yang M; Zhao P
    Lipids Health Dis; 2019 Feb; 18(1):40. PubMed ID: 30711009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body mass index and cardiovascular outcomes in patients with acute coronary syndrome by diabetes status: the obesity paradox in a Korean national cohort study.
    Park SJ; Ha KH; Kim DJ
    Cardiovasc Diabetol; 2020 Nov; 19(1):191. PubMed ID: 33172464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin-treated diabetes mellitus and predictors of mid-term clinical outcome after percutaneous coronary interventions with stent implantation.
    Tarantini G; Briguori C; Stankovic G; Takagi T; Corvaja N; Di Mario C; Colombo A
    Ital Heart J; 2003 Dec; 4(12):843-9. PubMed ID: 14976848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The burden of major adverse cardiac events in patients with coronary artery disease.
    Tsai IT; Wang CP; Lu YC; Hung WC; Wu CC; Lu LF; Chung FM; Hsu CC; Lee YJ; Yu TH
    BMC Cardiovasc Disord; 2017 Jan; 17(1):1. PubMed ID: 28052754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased Hazard of Myocardial Infarction With Insulin-Provision Therapy in Actively Smoking Patients With Diabetes Mellitus and Stable Ischemic Heart Disease: The BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Trial.
    Khan AA; Chung MJ; Novak E; Brown DL
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28903941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
    Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry).
    Shah B; Baber U; Pocock SJ; Krucoff MW; Ariti C; Gibson CM; Steg PG; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Iakovou I; Dangas G; Aquino MB; Sartori S; Chieffo A; Moliterno DJ; Colombo A; Mehran R
    Circ Cardiovasc Interv; 2017 Sep; 10(9):. PubMed ID: 28916600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic role of soluble ST2 in acute coronary syndrome with diabetes.
    Jha D; Goenka L; Ramamoorthy T; Sharma M; Dhandapani VE; George M
    Eur J Clin Invest; 2018 Sep; 48(9):e12994. PubMed ID: 29992539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
    Schwartz GG; Gabriel Steg P; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Jukema JW; Kim YU; Li QH; Manvelian G; Pordy R; Sourdille T; White HD; Szarek M;
    Circulation; 2021 Mar; 143(11):1109-1122. PubMed ID: 33438437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry.
    Ge Z; Baber U; Claessen BE; Farhan S; Chandrasekhar J; Li SX; Sartori S; Kini AS; Rao SV; Weiss S; Henry TD; Vogel B; Sorrentino S; Faggioni M; Kapadia S; Muhlestein B; Strauss C; Toma C; DeFranco A; Effron MB; Keller S; Baker BA; Pocock S; Dangas G; Mehran R
    Catheter Cardiovasc Interv; 2019 Feb; 93(3):E112-E119. PubMed ID: 30351514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
    Hagström E; Roe MT; Hafley G; Neely ML; Sidhu MS; Winters KJ; Prabhakaran D; White HD; Armstrong PW; Fox KA; Ohman EM; Boden WE;
    Clin Cardiol; 2016 Jun; 39(6):329-37. PubMed ID: 27177240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.